Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Non-Current Assets (2018 - 2025)

Summit Therapeutics' Non-Current Assets history spans 8 years, with the latest figure at $15.3 million for Q3 2025.

  • For Q3 2025, Non-Current Assets rose 21.5% year-over-year to $15.3 million; the TTM value through Sep 2025 reached $54.9 million, up 4.9%, while the annual FY2024 figure was $11.8 million, 10.78% down from the prior year.
  • Non-Current Assets reached $15.3 million in Q3 2025 per SMMT's latest filing, up from $14.8 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $26.5 million in Q3 2021 to a low of $6.9 million in Q1 2023.
  • Average Non-Current Assets over 5 years is $14.7 million, with a median of $13.5 million recorded in 2023.
  • Peak YoY movement for Non-Current Assets: crashed 59.68% in 2023, then skyrocketed 96.74% in 2024.
  • A 5-year view of Non-Current Assets shows it stood at $16.1 million in 2021, then crashed by 53.58% to $7.5 million in 2022, then surged by 77.53% to $13.2 million in 2023, then decreased by 10.78% to $11.8 million in 2024, then increased by 29.24% to $15.3 million in 2025.
  • Per Business Quant, the three most recent readings for SMMT's Non-Current Assets are $15.3 million (Q3 2025), $14.8 million (Q2 2025), and $13.1 million (Q1 2025).